Original articleLong-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents
Section snippets
Methods
The study was approved by our institutional review board.
Results
Twelve of the 73 patients (16.4%) developed a recurrence of onychomycosis during the follow-up period (Table I). This included 9 men and 3 women with age at initial diagnosis of onychomycosis between 21 and 79 years (average age 50 years). The duration of onychomycosis before therapy had been on average 2 years (8 months-5 years). The relapse occurred on average after 3 years from the end of therapy (1-5 years). All patients who relapsed developed a distal subungual onychomycosis of one (10
Discussion
Our study assessed the incidence of long-term relapses of onychomycosis of the toenails caused by dermatophytes and cured by treatment with systemic T or I. We only included patients who were mycologically negative with complete clinical cure 12 months after completion of systemic treatment. We excluded patients who were treated for longer than 3 months, and those who had been treated with both a systemic treatment and a topical antifungal or nail avulsion. Also excluded were patients with
References (10)
- et al.
Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum
J Am Acad Dermatol
(1996) - et al.
Chronic dermatophytosis caused by Trichophyton rubrum
J Am Acad Dermatol
(1996) - et al.
Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study
Arch Dermatol
(2002) - et al.
Onychomycosis in clinical practice: factors contributing to recurrence
Br J Dermatol
(2003) - et al.
Patients at risk of onychomycosis–risk factor identification and active prevention
J Eur Acad Dermatol Venereol
(2005)
Cited by (111)
Evaluation of cellulose based films comprising tea tree oil against dermatophytes and yeasts
2021, European Journal of Pharmaceutical SciencesCitation Excerpt :Onychomycosis is infection caused by nondermatophytic molds and yeasts: tinea unguium is caused by dermatophytes, which affects 20 % of the population across the world and constituting 50 % of all the nail diseases (Lipner and Scher, 2019). Onychomycosis affects patients with human immunodeficiency virus and further strikes one third of patients with diabetes increasing the severity of foot disorders (Piraccini et al., 2010). Success in treating onychomycosis is overshadowed by several limitations.
Efficacy and safety of topical terbinafine 10% solution (MOB-015) in the treatment of mild to moderate distal subungual onychomycosis: A randomized, multicenter, double-blind, vehicle-controlled phase 3 study
2021, Journal of the American Academy of DermatologyTransungual Drug Delivery System for the Topical Treatment of Onychomycosis: A Review
2022, Drug Delivery LettersNail Society of India (NSI) recommendations for pharmacologic therapy of onychomycosis
2023, Indian Dermatology Online Journal
Funding sources: None.
Conflicts of interest: None declared.